expect impli growth
top/bottom
maintain sale rais ep tax
vs street sales/ep rang impli growth
midpoint tax rate ad variabl chang yield ep
swing sale in-lin
see downsid keytruda sale street
mrk file significantli longer os/pf data
read-out elcc/aacr expect boost sentiment azn lynparza
collabor underappreci street reiter pt
rang expect impli growth top/bottom
expect issu revenu rang vs our/
street estim lower tax rate
street yield ep prior
expect mrk dilut ep rang vs our/street
estim mid-point sales/ep rang impli
growth vs recal comment investor
confer earli januari compani expect overal blend tax
rate lower onward result tax cut job act
note us major pharma preview click note
expect lower corpor us tax rate add upsid ep estim everi
drop mrk tax rate add bottom-lin mrk
os endpoint keytruda first-mov advantag nsclc maintain
click upgrad note believ keytruda data-readout
indication-specif approv drive global uptak reiter pt
ep support dcf analysi risk includ clinic
regulatori commerci challeng product launch keytruda steglatro
tr target
note recent click upgrad note posit overal surviv os benefit
achiev enabl keytruda maintain first-mov advantag
nsclc expect file us/eu respect
one broadest clinic trial program trial tumor type
along combin trial keytruda domin io market wall-of-data
extend mrk collabor astrazeneca azn
rate lynparza parp deal lynparza lead parp inhibitor underappreci
street click note azn-mrk collabor chart extens life-cycle program
lynparza potenti launch go forward approval/launch inhibitor
steglatro ertugliflozin partner add leg growth mrk diabet franchis three
dose ertugliflozin monotherapi sitagliptin metformin receiv posit opinion european
committe medicin product human use chmp recent set stage posit
regulatori decis european commiss mrk virolog vaccin busi face
competit buy mavyret take share zepati hcv ii
zostavax declin face glaxosmithklin gsk rate shingrix gardasil stagnat
due dose regimen chang gsk shingrix also receiv opinion eu chmp
sale ep in-lin street exhibit
model total revenu yoy underli fx
street model keytruda estim us ex-u
street estim keytruda market share us immuno-
oncolog market around accord latest symphoni health data click
note see downsid keytruda us sale estim base gross sale
data outsid oncolog sale estim street
bridion partial off-set lower street estim gardasil
 cancida gross margin street
opex estim slightli street sg estim
street estim street tax
rate model in-lin street ep yoy
in-lin street
catalyst focus keytruda pipelin asset
plan share interim result upcom medic meet elcc geneva
switzerland apr and/or chicago apr submit data
regulatori author expect file us/eu respect
expect file keytruda snda hepatocellular carcinoma base
data near-term fda approv expect click note
gi present data mrk/azn plan submit eu applic approv
lynparza germlin brca mutant breast cancer result lynparza trial
ovarian cancer also expect pdufa mrk doravirin nnrti hiv set
oct competit catalyst includ bristol buy
data roch rog-ch rate os data azn mystic os data
page
page
strh estimatesconsensusactualno ofdeltadelta cig women healthcardiovascular vytorin medicin women health nuvar implanon follistim dulera isentress invanz noxafil bridion sugammadex primaxin brandsrespiratori nasonex cozaar hyzaar gardasil proquad m-m-r ii health estimatesconsensusactualno ofdeltadelta cig statementtot incom dilut share estimatesconsensusactualno ofdeltadeltamargin margin margin merck co inc
page
rang rang rang rang rang midpointsstrh estimatesconsensu hit fx gross marginup vs providednot providednot providednot moder increas yoy admin flat providednot providednot providednot vs providednot providednot providednot oper expensesup low singl digitsup low singl digitsup mid singl digitsup mid singl incomenot providednot providednot providednot providednot expens providednot providednot providednot providednot incomenot providednot providednot providednot providednot net incomenot providednot providednot providednot providednot share yellow indic updat rangesstrh expect rang midpointsstrh expectationsstrh estimatesconsensu gross marginnot providednot admin levelsnot levelsnot oper expensesflat vs incomenot providednot expens providednot incomenot providednot blend tax rate lower net incomenot providednot epsnot providednot share oustandingnot providednot yellow indic updatesnot green indic strh expect rang merck co inc
page
datecompanyproductev categoryev pfeertugliflozinregulatoryema actiondecis ertugliflozin maa type diabet ertug monotherapi ertug sitagliptin ertug metformin feb keytruda r/r classic hodgkin lymphoma primari completionmarch releasephas virolog suppress hiv patient drive-shift trial march releaseph keytruda chemo trial non-squam nsclc primari completionapr approv expect keytruda r/r primari mediastin larg b-cell lymphoma pmbcl prioriti reviewapr releaseelcc expect interim read-out ph keytruda chemo trial non-squam nsclcapr releaseaacr expect interim read-out ph keytruda chemo trial non-squam tremelimumabclinicaldata releaseo data mystic trial expect releaseroch tecentriq chemo /- avastin os resultsjun releaseprimari complet bladder cancer jul advanc metastat nsclcoct pneumococc vaccin conjug phase studi vs prevnar infant popul oct approv expect doravirin nda combo antiretrovir tnbc keytruda monotherapi studyfeb completionprimari complet ph keytruda chemo trial non-squam nsclcjul apec studi patient prodrom alzheim diseasedec tnbc keytruda chemo studi merck co inc
exhibit quarterli ep surpris histori
page
periodactualmeansurp amtsurp estlowhighpric imp us sale sale growthim growthpric increas price increasesupsid downsid pi pi pi pi pi pi pi pi price pi pi pi pi pi pi pi pi pi pi pi pi pi price price increaseperi-lo pi pi pi pi global net upside/downsid sale ep im gross sale dec sale estim base symphoni health gross sale strh gross-net assumpt merck co inc
page
fye dec materi market research incom depreci total incom expens analysi gross market research oper pre-tax tax net chang gross market research oper pre-tax net metricspric merck co inc
page
fye dec short-term account prepaid expens tax current net properti plant intang loan payabl current portion lt account payabl accru incom tax dividend long-term defer incom tax non-current liabil paid-in comprehens co inc sharehold sharehold sharehold equiti merck co inc
exhibit statement flow
page
fye dec net compensaton asset impair incom dividend from tax work secur secur sale short-term issuanc lt long term treasuri stock exchang begin end merck co inc
merck co inc commit premier research-intens biopharmaceut
compani strategi discov develop provid innov product servic save
improv live around world innov medicin vaccin anim health product
gener us ex-u total revenu merck core area
focu oncolog diabet infecti diseas vaccin account
sale respect sever key brand product oncolog keytruda diabet januvia/
janumet/marizev japan virolog zepati drive growth addit growth opportun
immunolog women vaccin along grow biosimilar portfolio mrk anim
busi repres sale repres total sale
rate buy price target key global leader immuno-oncolog io
market flagship asset keytruda establish foundat io asset approv
favor clinic data multipl tumor type keytruda earlier expect posit result
non-smal cell lung cancer nsclc sourc upsid allow maintain first-mov
advantag import indic
one broadest clinic trial program trial
tumor type along combin trial sinc septemb keytruda approv
key indic us also grant number breakthrough therapi
design keytruda domin io market wall-of-data extend
mrk collabor astrazeneca lynparza parp deal
diabet mrk januvia/janumet franchis pressur type diabet market move
away toward newer effect agent like growth
mrk diabet franchis expect come inhibitor steglatro ertugliflozin
weekli marizev launch japan insulin conjug expect
launch
outsid oncolog anim health continu show strong growth think mrk
franchis consider competit pressur signific pressur come
virolog busi also see modest downward pressur mrk vaccin busi
zostavax face competit glaxosmithklin shingrix gardasil expect declin
us/eu due adopt two dose regimen vs previou three dose
model sales/ep cagr vs street
valuat risk
target price assum merck trade ep estim support
discount cash flow dcf model multipl ep group averag
think appropri given mrk leadership immuno-oncolog space
keytruda first-mov advantag nsclc
risk rate target price includ failur capit truda first-mov advantag
nsclc approv use januvia franchis see materi declin sale due rise
competit oral dpp-iv segment clinic regulatori risk keytruda
relebactam infect herp zoster valent pneumococc vaccin
global price risk invest risk relat biopharmaceut industri includ global price risk
payer polit risk clinic develop risk regulatori risk commerci risk legal
risk patent challeng
compani mention note
page
astrazeneca plc azn rate
glaxosmithklin plc gsk rate
roch hold limit rog-ch rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
